{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179446","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.378787+00:00","generated_at":"2026-05-17T14:07:16.537814+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XOMA Royalty Q2 net income $9.2M; acquires Turnstone, HilleVax, LAVA; H1 cash receipts $29.6M","bullets":["Net income $9.2M (Q2 2025) vs $16.0M (Q2 2024); income & revenue $13.1M vs $11.1M.","H1 2025 cash receipts $29.6M ($16.0M royalties, $13.6M milestones); Q2 cash receipts $11.7M.","Completed Turnstone acquisition (Aug 11); HilleVax expected Sept; LAVA expected Q4 2025.","Deployed $20M for additional mezagitamab royalty; $5M milestone from Rezolute, $3M from Takeda.","Repurchased 107,500 shares in H1 for $2.4M; paid $2.7M in preferred stock dividends."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179446","json":"https://secwatch.observer/filing/0001193125-25-179446.json","markdown":"https://secwatch.observer/filing/0001193125-25-179446.md","text":"https://secwatch.observer/filing/0001193125-25-179446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/0001193125-25-179446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312525179446/d852650d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:07:16.537814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}